Medicover AB (MCOV.B) AI Stock Analysis

• Market Cap: kr36.39B
• Dividend Yield: 0.69%
• Average Volume (3M): 104.55K
• Price to Earnings (P/E): 104.3
• Beta (1Y): 0.48
• Revenue Growth: 18.16%
• EPS Growth: 35.85%
• Country: SE
• Employees: 47,000
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Care Facilities
• EPS (TTM): 1.45
• Shares Outstanding: 74,347,420
• 10 Day Avg. Volume: 103,214
• 30 Day Avg. Volume: 104,546
• PEG Ratio: -10.98
• Price to Book (P/B): 4.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 56.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: ―

Medicover AB's stock score is driven by strong financial performance and positive technical indicators, tempered by concerns over high leverage and a high P/E ratio suggesting overvaluation. Efficient cash flow management and robust revenue growth are significant strengths, but investors should be cautious of the stock's valuation metrics.

Medicover AB Business Overview & Revenue Model

Company Description

Medicover AB is a leading international healthcare and diagnostic services company headquartered in Sweden. The company operates through two main divisions: Healthcare Services and Diagnostic Services. Medicover provides a wide range of healthcare services including primary care, specialist outpatient care, and hospital services. In diagnostics, the company offers comprehensive laboratory testing and imaging services. Medicover operates across several countries, predominantly in Central and Eastern Europe, and is committed to delivering high-quality healthcare services to improve patient outcomes.

How the Company Makes Money

Medicover AB generates revenue primarily through its two main divisions: Healthcare Services and Diagnostic Services. In the Healthcare Services division, the company earns money by providing medical care services, which include outpatient consultations, inpatient care, and various medical procedures. This division serves both insured and non-insured patients, with a significant portion of revenue coming from contracts with insurance companies and corporate clients. The Diagnostic Services division contributes to revenue by offering laboratory and imaging services to hospitals, clinics, and individual patients. Medicover's revenue model is heavily reliant on its extensive network of clinics and diagnostic centers, strategic partnerships with healthcare providers, and contracts with health insurance companies, which ensure a steady flow of patients and service utilization.

Medicover AB Financial Statement Overview

Summary

Medicover AB shows strong revenue growth and improving profitability metrics. The high leverage indicated by the debt-to-equity ratio poses a potential risk, but efficient cash flow management helps offset this concern.

Income Statement

Medicover AB has demonstrated strong revenue growth with a 37.6% increase from 2023 to 2024 and a 21.2% increase from 2022 to 2023. The TTM (Trailing-Twelve-Months) revenue growth rate stands at 3.8%. The gross profit margin for the TTM is 21.9%, showing efficient cost management. EBIT margin has increased slightly to 4.0% in the TTM, while EBITDA margin improved to 13.6%, indicating better operational efficiency. Net profit margin is modest at 1.4% in the TTM, but it reflects steady profitability with potential for future growth.

Balance Sheet

The company's debt-to-equity ratio has increased to 2.55 in the TTM, which indicates high leverage and potential risk if not managed properly. However, the return on equity (ROE) has improved to 6.3% in the TTM, suggesting improved profitability from equity. The equity ratio stands at 22.4% for the TTM, reflecting a stable, though leveraged, capital structure.

Cash Flow

Medicover AB's cash flow is strong, with a free cash flow growth of 6.6% in the TTM. The operating cash flow to net income ratio is high at 8.87, indicating good cash generation relative to profits. The free cash flow to net income ratio of 4.86 further highlights efficient cash flow management, demonstrating the company's ability to convert profits into cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.17B	2.09B	1.75B	1.51B	1.38B	997.80M
	Gross Profit
476.40M	448.30M	359.40M	335.60M	395.00M	263.50M
	EBIT
87.30M	70.30M	61.40M	55.50M	159.40M	61.30M
	EBITDA
294.50M	277.10M	257.40M	215.90M	274.90M	151.60M
	Net Income Common Stockholders
30.60M	16.70M	17.60M	11.80M	101.80M	25.80M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
113.20M	82.80M	64.40M	49.10M	277.90M	86.80M
	Total Assets
2.18B	2.14B	1.94B	1.83B	1.68B	1.11B
	Total Debt
1.25B	1.24B	1.00B	940.00M	764.60M	367.40M
	Net Debt
1.15B	1.17B	952.90M	899.60M	682.70M	320.70M
	Total Liabilities
1.67B	1.65B	1.41B	1.32B	1.12B	627.40M
	Stockholders Equity
487.70M	464.80M	496.50M	474.70M	517.60M	448.00M
Cash Flow		Free Cash Flow
148.80M	139.60M	94.50M	29.60M	114.50M	83.50M
	Operating Cash Flow
271.40M	261.90M	205.00M	170.20M	216.70M	156.00M
	Investing Cash Flow
-128.10M	-134.70M	-119.80M	-184.80M	-333.60M	-126.30M
	Financing Cash Flow
-114.30M	-108.00M	-73.70M	-24.30M	164.10M	-14.10M

Medicover AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 239.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCOV.B, the sentiment is Neutral. The current price of 239.5 is above the 20-day moving average (MA) of 239.40, above the 50-day MA of 227.62, and above the 200-day MA of 200.12, indicating a neutral trend. The MACD of 2.43 indicates Positive momentum. The RSI at 50.52 is Neutral, neither overbought nor oversold. The STOCH value of 48.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:MCOV.B.

Medicover AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALIF.B	75 Outperform	kr23.54B	76.12	5.83%	0.39%	6.33%	291.12%
ATT	71 Outperform	kr9.27B	18.34		1.96%	9.68%	31.27%
HUM	68 Neutral	€1.91B	9.65	6.38%	2.72%	8.43%	24.08%
MCOV.B	66 Neutral	kr36.39B	104.28		0.69%	18.16%	35.85%
VITR	65 Neutral	kr18.91B	37.96	3.79%	0.79%	3.17%	―
VIMIAN	64 Neutral	kr20.87B	95.26	3.18%	―	16.00%	126.41%
Sector *	54 Neutral	$5.25B	3.27	-44.35%	6.27%	16.79%	-0.10%

Medicover AB Corporate Events

Medicover Appoints New Chief Digital Information Officer

Medicover AB has announced the appointment of Lukasz Krause as the new Chief Digital Information Officer (CDIO), effective 1 July 2025. Krause, who has been with Medicover for three years as the Head of IT for the Healthcare Services division, brings extensive IT management experience from international corporations. He succeeds Jarek Urbanczyk, who is leaving after nearly six years. The company believes Krause’s expertise will ensure technology continues to drive Medicover’s future success.

Medicover’s MRD Assay Shows Promise in Lung Cancer Detection

Medicover AB has announced promising interim results from the DART clinical study, which indicate that their minimal residual disease (MRD) assay can effectively detect MRD in lung cancer patients. This development marks a significant milestone towards the clinical validation and potential commercialization of their MRD assay, which could help identify high-risk patients and guide tailored interventions, thereby impacting the company’s market positioning in the genetics and diagnostics sector.